If you look at the Bell Financial model they have valued Trofinetide based on Retts and Fragile X patients only and their relative market sizes.
The key take out is the patent for the entire Autism spectrum. If it helps Retts it will likely help regular autism which also a market with an unmet need. The market potential is massive if you look at
https://www.autismspectrum.org.au/content/what-autism
they estimate 1/100 people have some form of Autism.
You have to think Trofinetide is going to have a massive off label opportunity especially with the oral dosing and supreme safety profile. We are talking blockbuster potential.
Ann: First patent in Japan granted for Neuren's trofinetide, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.08 |
Change
0.225(1.75%) |
Mkt cap ! $1.635B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $4.936M | 376.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 100 | $13.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.08 | 229 | 2 |
View Market Depth
| Last trade - 13.25pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |